{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:24:54Z","timestamp":1794579894383,"version":"4.9.1"},"reference-count":69,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA006927"],"award-info":[{"award-number":["CA006927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA201045"],"award-info":[{"award-number":["CA201045"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["DE030707"],"award-info":[{"award-number":["DE030707"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>More than 600,000 cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed globally each year. Many HNSCCs overexpress the ERBB family member epidermal growth factor receptor (EGFR), and EGFR inhibitors (EGFRi) and pan-ERBB inhibitors (ERBBi) are clinically active in the treatment of locally advanced, metastatic, or recurrent HNSCC. However, resistance to these inhibitors typically develops, often associated with epithelial\u2013mesenchymal transition (EMT). Aurora kinase A (AURKA), a mitotic regulator with expanded signaling functions in tumors, has been reported to reverse EGFR resistance in EGFR-mutated lung cancer. To identify strategies to overcome resistance in HNSCC, we developed HNSCC cell models that were treatment-na\u00efve parental or selected for resistance to the EGFRi erlotinib or the ERBBi afatinib. The resistant HNSCC models had typically undergone partial EMT, consistent with clinical resistance, associated with upregulation of the AURKA partner protein NEDD9. Synergy of the AURKA inhibitor VIC-1911 with erlotinib or afatinib in parental models was reduced in resistant models in short-term growth assays. In longer-term clonogenic assays and in vivo, cells selected for EGFRi\/ERBBi resistance showed heightened sensitivity to VIC-1911, contributing to reduced synergy. Based on increased AURKA dependence, we compared the combination of VIC-1911 with adavosertib, an inhibitor of the cell-cycle checkpoint regulator WEE1, in parental and resistant models. These showed a combination effect both in vitro and in vivo that was retained in ERBBi-resistant xenografts, suggesting the potential value of combined AURKA and WEE1 inhibitor use in patients with ERBBi-resistant HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Treatment resistance is a major source of mortality for HNSCC. This study investigates strategies to overcome resistance to inhibitors of the ERBB family, which are commonly used for the treatment of advanced HNSCC. The results suggest the value of the use of combined AURKA and WEE inhibition in the resistance setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0368","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:47:01Z","timestamp":1785433621000},"page":"1916-1932","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor\u2013Resistant Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1800","authenticated-orcid":false,"given":"Flaviane N.","family":"Silva","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."},{"name":"2Drexel University College of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8352-4269","authenticated-orcid":false,"given":"Jong Woo","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03j7sze86","id-type":"ROR","asserted-by":"publisher"}],"name":"Yale Cancer Center 3 Section of Medical Oncology, Department of Internal Medicine, , Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9568-6699","authenticated-orcid":false,"given":"Theodore T.","family":"Nguyen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."},{"name":"2Drexel University College of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3726-0409","authenticated-orcid":false,"given":"Fiona M.","family":"Goeckel","sequence":"additional","affiliation":[{"name":"4Chestnut Hill College, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6825-2313","authenticated-orcid":false,"given":"Tetyana","family":"Bagnyukova","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-4454","authenticated-orcid":false,"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3618-3673","authenticated-orcid":false,"given":"Erica A.","family":"Golemis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."},{"name":"5Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4660-1859","authenticated-orcid":false,"given":"Barbara A.","family":"Burtness","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03j7sze86","id-type":"ROR","asserted-by":"publisher"}],"name":"Yale Cancer Center 3 Section of Medical Oncology, Department of Internal Medicine, , Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2026081306263296400_bib1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026081306263296400_bib2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/PPO.0000000000000115","article-title":"Prevalence of human papillomavirus in oropharyngeal cancer: a systematic review","volume":"21","author":"Stein","year":"2015","journal-title":"Cancer J"},{"key":"2026081306263296400_bib3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","article-title":"The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53","volume":"75","author":"Scheffner","year":"1993","journal-title":"Cell"},{"key":"2026081306263296400_bib4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0092-8674(89)90839-8","article-title":"The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus","volume":"58","author":"Dyson","year":"1989","journal-title":"Cell"},{"key":"2026081306263296400_bib5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41199-016-0003-z","article-title":"Genomic insights into head and neck cancer","volume":"1","author":"Beck","year":"2016","journal-title":"Cancers Head Neck"},{"key":"2026081306263296400_bib6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026081306263296400_bib7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2026081306263296400_bib8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/bjc.1994.322","article-title":"Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts","volume":"70","author":"Stanton","year":"1994","journal-title":"Br J Cancer"},{"key":"2026081306263296400_bib9","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026081306263296400_bib10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2026081306263296400_bib11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.oraloncology.2019.02.026","article-title":"PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma","volume":"91","author":"Eze","year":"2019","journal-title":"Oral Oncol"},{"key":"2026081306263296400_bib12","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1002\/hed.28152","article-title":"Phase II trial of chemotherapy, cetuximab, and erlotinib in patients with metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"47","author":"Bhatia","year":"2025","journal-title":"Head Neck"},{"key":"2026081306263296400_bib13","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.3390\/cancers14102355","article-title":"Phase II trial of CDX-3379 and cetuximab in recurrent\/metastatic, HPV-negative, cetuximab-resistant head and neck cancer","volume":"14","author":"Bauman","year":"2022","journal-title":"Cancers"},{"key":"2026081306263296400_bib14","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/hed.27077","article-title":"Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients","volume":"44","author":"Forman","year":"2022","journal-title":"Head Neck"},{"key":"2026081306263296400_bib15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2012.46.3299","article-title":"Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial","volume":"31","author":"Martins","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026081306263296400_bib16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(15)70124-5","article-title":"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial","volume":"16","author":"Machiels","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026081306263296400_bib17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaoncol.2019.1146","article-title":"Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck: a randomized clinical trial","volume":"5","author":"Burtness","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026081306263296400_bib18","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/annonc\/mdx344","article-title":"Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and\/or metastatic head and neck cancer","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann Oncol"},{"key":"2026081306263296400_bib19","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdu216","article-title":"A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"25","author":"Seiwert","year":"2014","journal-title":"Ann Oncol"},{"key":"2026081306263296400_bib20","doi-asserted-by":"publisher","first-page":"ra67","DOI":"10.1126\/scisignal.2001083","article-title":"Synthetic lethal screen of an EGFR-centered network to improve targeted therapies","volume":"3","author":"Astsaturov","year":"2010","journal-title":"Sci Signal"},{"key":"2026081306263296400_bib21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","article-title":"Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat Med"},{"key":"2026081306263296400_bib22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41416-024-02649-z","article-title":"Inhibition of the AURKA\/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells","volume":"130","author":"Rio-Vilari\u00f1o","year":"2024","journal-title":"Br J Cancer"},{"key":"2026081306263296400_bib23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/PPO.0000000000000614","article-title":"Aurora kinases as therapeutic targets in head and neck cancer","volume":"28","author":"Nguyen","year":"2022","journal-title":"Cancer J"},{"key":"2026081306263296400_bib24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026081306263296400_bib25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaoncol.2022.7949","article-title":"Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026081306263296400_bib26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026081306263296400_bib27","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1158\/1078-0432.CCR-18-0440","article-title":"Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026081306263296400_bib28","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026081306263296400_bib29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the Cancer Dependency Map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2026081306263296400_bib30","doi-asserted-by":"publisher","first-page":"e08905","DOI":"10.7554\/eLife.08905","article-title":"Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation","volume":"4","author":"\u0160olman","year":"2015","journal-title":"eLife"},{"key":"2026081306263296400_bib31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026081306263296400_bib32","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.3390\/cancers13215355","article-title":"Epithelial-to-mesenchymal transition-derived heterogeneity in head and neck squamous cell carcinomas","volume":"13","author":"Baumeister","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026081306263296400_bib33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-024-01954-8","article-title":"Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome","volume":"23","author":"Broghammer","year":"2024","journal-title":"Mol Cancer"},{"key":"2026081306263296400_bib34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2023.10.001","article-title":"Transcriptional regulation of EMT transcription factors in cancer","volume":"97","author":"Saitoh","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"2026081306263296400_bib35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.job.2022.02.004","article-title":"The role of partial-EMT in the progression of head and neck squamous cell carcinoma","volume":"64","author":"Kisoda","year":"2022","journal-title":"J Oral Biosci"},{"key":"2026081306263296400_bib36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.004","article-title":"TGF-beta, EMT, and resistance to anti-cancer treatment","volume":"97","author":"Wang","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"2026081306263296400_bib37","doi-asserted-by":"publisher","first-page":"1336577","DOI":"10.3389\/fonc.2024.1336577","article-title":"Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma","volume":"14","author":"Guo","year":"2024","journal-title":"Front Oncol"},{"key":"2026081306263296400_bib38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s1097-2765(03)00392-7","article-title":"Structural basis of Aurora-A activation by TPX2 at the mitotic spindle","volume":"12","author":"Bayliss","year":"2003","journal-title":"Mol Cell"},{"key":"2026081306263296400_bib39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/ncb1309","article-title":"The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome","volume":"7","author":"Pugacheva","year":"2005","journal-title":"Nat Cell Biol"},{"key":"2026081306263296400_bib40","doi-asserted-by":"publisher","first-page":"e22102","DOI":"10.1371\/journal.pone.0022102","article-title":"NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation","volume":"6","author":"Tikhmyanova","year":"2011","journal-title":"PLoS One"},{"key":"2026081306263296400_bib41","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1038\/s41388-018-0296-y","article-title":"NEDD9 promotes oncogenic signaling, a stem\/mesenchymal gene signature, and aggressive ovarian cancer growth in mice","volume":"37","author":"Gabbasov","year":"2018","journal-title":"Oncogene"},{"key":"2026081306263296400_bib42","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.1158\/0008-5472.CAN-07-1328","article-title":"A new central scaffold for metastasis: parsing HEF1\/Cas-L\/NEDD9","volume":"67","author":"O\u2019Neill","year":"2007","journal-title":"Cancer Res"},{"key":"2026081306263296400_bib43","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.3390\/ijms26051830","article-title":"Spatial transcriptomic analysis of surgical resection specimens of primary head and neck squamous cell carcinoma treated with afatinib in a window-of-opportunity Study (EORTC90111-24111)","volume":"26","author":"Beyaert","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026081306263296400_bib44","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1074\/jbc.M111.312090","article-title":"Activation of Aurora-A kinase by protein partner binding and phosphorylation are independent and synergistic","volume":"287","author":"Dodson","year":"2012","journal-title":"J Biol Chem"},{"key":"2026081306263296400_bib45","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","article-title":"Cancer drug resistance induced by EMT: novel therapeutic strategies","volume":"95","author":"De Las Rivas","year":"2021","journal-title":"Arch Toxicol"},{"key":"2026081306263296400_bib46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2015.04.086","article-title":"Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases","volume":"567","author":"Shagisultanova","year":"2015","journal-title":"Gene"},{"key":"2026081306263296400_bib47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4161\/cc.5.4.2439","article-title":"HEF1-Aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks","volume":"5","author":"Pugacheva","year":"2006","journal-title":"Cell Cycle"},{"key":"2026081306263296400_bib48","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"2026081306263296400_bib49","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"2026081306263296400_bib50","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.15252\/embr.201643030","article-title":"Drugging the addict: non-oncogene addiction as a target for cancer therapy","volume":"17","author":"Nagel","year":"2016","journal-title":"EMBO Rep"},{"key":"2026081306263296400_bib51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"2026081306263296400_bib52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","article-title":"EGFR-targeted therapies in the post-genomic era","volume":"36","author":"Xu","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"2026081306263296400_bib53","doi-asserted-by":"publisher","first-page":"935","DOI":"10.4161\/cbt.20846","article-title":"Preclinical modeling of EGFR inhibitor resistance in head and neck cancer","volume":"13","author":"Quesnelle","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"2026081306263296400_bib54","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11523-014-0353-6","article-title":"Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo","volume":"10","author":"Young","year":"2015","journal-title":"Target Oncol"},{"key":"2026081306263296400_bib55","doi-asserted-by":"publisher","first-page":"18793","DOI":"10.1038\/s41598-019-55208-5","article-title":"MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma","volume":"9","author":"Jain","year":"2019","journal-title":"Sci Rep"},{"key":"2026081306263296400_bib56","doi-asserted-by":"publisher","first-page":"76087","DOI":"10.18632\/oncotarget.12590","article-title":"Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma","volume":"7","author":"Stanam","year":"2016","journal-title":"Oncotarget"},{"key":"2026081306263296400_bib57","doi-asserted-by":"publisher","first-page":"31785","DOI":"10.1074\/jbc.M805880200","article-title":"Aurora A is essential for early embryonic development and tumor suppression","volume":"283","author":"Lu","year":"2008","journal-title":"J Biol Chem"},{"key":"2026081306263296400_bib58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/cells14020133","article-title":"Exploiting cancer dormancy signaling mechanisms in epithelial ovarian cancer through spheroid and organoid analysis","volume":"14","author":"Tomas","year":"2025","journal-title":"Cells"},{"key":"2026081306263296400_bib59","doi-asserted-by":"publisher","first-page":"15521","DOI":"10.1021\/acs.jmedchem.4c01165","article-title":"Selective Aurora A-TPX2 interaction inhibitors have in vivo efficacy as targeted antimitotic agents","volume":"67","author":"Stockwell","year":"2024","journal-title":"J Med Chem"},{"key":"2026081306263296400_bib60","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","article-title":"Aurora A kinase (AURKA) in normal and pathological cell division","volume":"70","author":"Nikonova","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"2026081306263296400_bib61","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.1073\/pnas.1610626113","article-title":"Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors","volume":"113","author":"Richards","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081306263296400_bib62","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/nm.4107","article-title":"A MYC-Aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer","volume":"22","author":"Dauch","year":"2016","journal-title":"Nat Med"},{"key":"2026081306263296400_bib63","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-21-4316","article-title":"Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer","volume":"28","author":"Deneka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026081306263296400_bib64","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.4161\/cc.21732","article-title":"p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation","volume":"11","author":"Wu","year":"2012","journal-title":"Cell Cycle"},{"key":"2026081306263296400_bib65","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of alisertib (MLN8237), an investigational small molecule inhibitor of Aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026081306263296400_bib66","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.canlet.2014.08.039","article-title":"Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins","volume":"354","author":"Boeckx","year":"2014","journal-title":"Cancer Lett"},{"key":"2026081306263296400_bib67","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-025-02353-3","article-title":"Aurora kinases signaling in cancer: from molecular perception to targeted therapies","volume":"24","author":"Vats","year":"2025","journal-title":"Mol Cancer"},{"key":"2026081306263296400_bib68","doi-asserted-by":"publisher","first-page":"104233","DOI":"10.1016\/j.critrevonc.2023.104233","article-title":"Adavosertib and beyond: biomarkers, drug combination and toxicity of WEE1 inhibitors","volume":"193","author":"Zhang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026081306263296400_bib69","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-24-1194","article-title":"Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors","volume":"24","author":"Ma","year":"2025","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0368\/3818426\/crc-26-0368.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1916\/3821045\/crc-26-0368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1916\/3821045\/crc-26-0368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:53:40Z","timestamp":1786618420000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/1916\/787417\/Combination-AURKA-and-WEE1-Inhibition-Exhibits"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0368","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33240557","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240578","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240548","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240569","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240560","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240593","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240581","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240551","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240584","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240572","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240575","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240563","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240566","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240587","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240554","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33240590","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8651582","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}